Adjuvant versus salvage radiotherapy following radical prostatectomy: do the AUA/ASTRO guidelines have all the answers?

References

• Stephenson AJ, Bolla M, Briganti A, et al. Postoperative radiation therapy for pathologically advanced prostate cancer after radical prostatectomy. Eur Urol 2012;61(3):443-51
   PubMed Web of Science ®Google Scholar
• Wiegel T, Bottke D, Bartkowiak D, et al. The 10-years follow-up of the ARO 96-02/AUO AP 09/95 trial on adjuvant radiotherapy (ART) versus wait-and-see (WS) after prostatectomy for pT3 cancer-subgroup analysis. Eur Urol Suppl 2013;12(1):e192-e3
   Google Scholar
• Bolla M, van Poppel H, Tombal B, et al. Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled trial (EORTC trial 22911). Lancet 2012;380(9858):2018-27
   PubMed Web of Science ®Google Scholar
• Thompson IM, Valicenti RK, Albertsen P, et al. Adjuvant and salvage radiotherapy after prostatectomy: AUA/ASTRO guideline. J Urol 2013;190(2):441-9
   PubMed Web of Science ®Google Scholar
• Schreiber D, Rineer J, Yu JB, et al. Analysis of pathologic extent of disease for clinically localized prostate cancer after radical prostatectomy and subsequent use of adjuvant radiation in a national cohort. Cancer 2010;116(24):5757-66
   PubMedGoogle Scholar
• Ghia AJ, Shrieve DC, Tward JD. Adjuvant radiotherapy use and patterns of care analysis for margin-positive prostate adenocarcinoma with extracapsular extension: postprostatectomy adjuvant radiotherapy: a SEER analysis. Urology 2010;76(5):1169-74
   PubMed Web of Science ®Google Scholar
• Evans SM, Millar JL, Davis ID, et al. Patterns of care for men diagnosed with prostate cancer in Victoria from 2008 to 2011. Med J Aust 2013;198(10):540-5
   PubMedGoogle Scholar
• Bolton D, Severi G, Millar JL, et al. A whole of population-based series of radical prostatectomy in Victoria, 1995 to 2000. Aust N Z J Public Health 2009;33(6):527-33
   PubMedGoogle Scholar
• Hoffman KE, Nguyen PL, Chen MH, et al. Recommendations for post-prostatectomy radiation therapy in the United States before and after the presentation of randomized trials. J Urol 2011;185(1):116-20
   PubMedGoogle Scholar
• Tyldesley S, Peacock M, Morris JW, et al. The need for, and utilization of prostate-bed radiotherapy after radical prostatectomy for patients with prostate cancer in British Columbia. Can Urol Assoc J 2012;6(2):89-94
   PubMedGoogle Scholar
• Thompson IM Jr, Tangen CM, Paradelo J, et al. Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial. JAMA 2006;296(19):2329-35
   PubMed Web of Science ®Google Scholar
• Wiegel T, Bottke D, Bartkowiak D, et al. Phase III results of adjuvant radiotherapy (RT) versus wait-and-see (WS) in patients with pT3 prostate cancer following radical prostatectomy (RP)(ARO 96-02/AUO AP 09/95): ten years follow-up. J Clin Oncol 2013;31:6
   Google Scholar
• Pound CR, Partin AW, Eisenberger MA, et al. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999;281(17):1591-7
   PubMed Web of Science ®Google Scholar
• Boorjian SA, Thompson RH, Tollefson MK, et al. Long-term risk of clinical progression after biochemical recurrence following radical prostatectomy: the impact of time from surgery to recurrence. Eur Urol 2011;59(6):893-9
   PubMed Web of Science ®Google Scholar
• Freedland SJ, Humphreys EB, Mangold LA, et al. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA 2005;294(4):433-9
   PubMed Web of Science ®Google Scholar
• Kattan MW, Wheeler TM, Scardino PT. Postoperative nomogram for disease recurrence after radical prostatectomy for prostate cancer. J Clin Oncol 1999;17(5):1499-507
   PubMed Web of Science ®Google Scholar
• Stephenson AJ, Scardino PT, Eastham JA, et al. Postoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. J Clin Oncol 2005;23(28):7005-12
   PubMed Web of Science ®Google Scholar
• Ramsden AR, Chodak G. An analysis of risk factors for biochemical progression in patients with seminal vesicle invasion: validation of Kattan’s nomogram in a pathological subgroup. BJU Int 2004;93(7):961-4
   PubMedGoogle Scholar
• Briganti A, Bianchi M, Joniau S, et al. Development and internal validation of a nomogram predicting biochemical recurrence after early salvage radiotherapy in prostate cancer patients treated with radical prostatectomy. J Urol 2013;189(4):e395
   Google Scholar
• Donin NM, Laze J, Zhou M, et al. Gleason 6 prostate tumors diagnosed in the PSA era do not demonstrate the capacity for metastatic spread at the time of radical prostatectomy. Urology 2013;82(1):148-52
   PubMedGoogle Scholar
• Abdollah F, Gandaglia G, Schiffmann J, et al. Adjuvant radiotherapy improves cancer-specific survival only in patients with highly aggressive prostate cancer. validation of recently released criteria. J Urol 2014;191(4):e351
   Google Scholar
• King CR. The timing of salvage radiotherapy after radical prostatectomy: a systematic review. Int J Radiat Oncol Biol Phys 2012;84(1):104-11
   PubMed Web of Science ®Google Scholar
• Stephenson AJ, Shariat SF, Zelefsky MJ, et al. Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy. JAMA 2004;291(11):1325-32
   PubMed Web of Science ®Google Scholar
• Siegmann A, Bottke D, Faehndrich J, et al. Salvage radiotherapy after prostatectomy - what is the best time to treat? Radiother Oncol 2012;103(2):239-43
   PubMedGoogle Scholar
• Briganti A, Wiegel T, Joniau S, et al. Early salvage radiation therapy does not compromise cancer control in patients with pT3N0 prostate cancer after radical prostatectomy: results of a match-controlled multi-institutional analysis. Eur Urol 2012;62(3):472-87
   PubMed Web of Science ®Google Scholar
• Stephenson AJ, Scardino PT, Kattan MW, et al. Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. Erratum appears in J Clin Oncol 2007;25(26):4153-J Clin Oncol 2007;25(15):2035-41
   Google Scholar
• Briganti A, Karnes RJ, Joniau S, et al. Prediction of outcome following early salvage radiotherapy among patients with biochemical recurrence after radical prostatectomy. Eur Urol 2014;66:479–486
   Google Scholar
• Trock BJ, Han M, Freedland SJ, et al. Prostate cancer-specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy. JAMA 2008;299(23):2760-9
   PubMed Web of Science ®Google Scholar
• Choueiri TK, Chen MH, D’Amico AV, et al. Impact of postoperative prostate-specific antigen disease recurrence and the use of salvage therapy on the risk of death. Cancer 2010;116(8):1887-92
   PubMed Web of Science ®Google Scholar
• Boorjian SA, Karnes RJ, Crispen PL, et al. Radiation therapy after radical prostatectomy: impact on metastasis and survival. J Urol 2009;182(6):2708-14
   PubMedGoogle Scholar
• Ost P, De Troyer B, Fonteyne V, et al. A matched control analysis of adjuvant and salvage high-dose postoperative intensity-modulated radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 2011;80(5):1316-22
   PubMed Web of Science ®Google Scholar
• Trabulsi EJ, Valicenti RK, Hanlon AL, et al. A multi-institutional matched-control analysis of adjuvant and salvage postoperative radiation therapy for pT3-4N0 prostate cancer. Urology 2008;72(6):1298-302. discussion 302-4
   PubMed Web of Science ®Google Scholar
• Kowalczyk KJ, Gu X, Nguyen PL, et al. Optimal timing of early versus delayed adjuvant radiotherapy following radical prostatectomy for locally advanced prostate cancer. Urol Oncol 2014;32(3):303-8
   PubMedGoogle Scholar
• Maurizi F, Bonetta A, Bortolus R, et al. Salvage or adjuvant? 5y-results of the nullAiro national working group on prostate radiotherapynull multicenter prospective study. Radiother Oncol 2011;99:S202
   Google Scholar
• Pazona JF, Han M, Hawkins SA, et al. Salvage radiation therapy for prostate specific antigen progression following radical prostatectomy: 10-year outcome estimates. J Urol 2005;174(4 Pt 1):1282-6
   PubMedGoogle Scholar
• Pfister D, Bolla M, Briganti A, et al. Early salvage radiotherapy following radical prostatectomy. Eur Urol 2014;65(6):1034-43
   PubMed Web of Science ®Google Scholar
• Mizowaki T, Aoki M, Nakamura K, et al. Current status and outcomes of salvage radiotherapy for patients with PSA recurrence after prostatectomy: a JROSG surveillance study. J Clin Oncol 2013;31:6
   Google Scholar
• Pearse M, Fraser-Browne C, Davis ID, et al. A Phase III trial to investigate the timing of radiotherapy for prostate cancer with high-risk features: background and rationale of the Radiotherapy – Adjuvant Versus Early Salvage (RAVES) trial. BJU Int 2014;113(Suppl 2):7-12
   PubMed Web of Science ®Google Scholar
• Parker C, Clarke N, Logue J, et al. RADICALS (Radiotherapy and Androgen Deprivation in Combination after Local Surgery). Clin Oncol 2007;19(3):167-71
   PubMed Web of Science ®Google Scholar
• Sydes MR, Vale C, Kneebone A, et al. Re: Andrew J. Stephenson, Michel Bolla, Alberto Briganti, et al. Postoperative radiation therapy for pathologically advanced prostate cancer after radical prostatectomy. Eur Urol 2012;61:443-51. Eur Urol 2012;62(6):e99
   Google Scholar